Fukushima Takuya




Researcher Number(JSPS Kakenhi)


Current Affiliation Organization 【 display / non-display

  • Duty   University of the Ryukyus   Faculty of Medicine   Health Sciences   Professor  

University 【 display / non-display

  • 1983.04

    Nagano University   Faculty of Medicine   Graduated

External Career 【 display / non-display

  • 1989.06

    Nagasaki University, Department of Hematology, Resident  

  • 1990.06

    National Nagasaki Center Hospital. Resident  

  • 1991.06

    Nagasaki University, Department of Hematology, Senior Resident  

  • 1992.09

    Kushiro North Hospital, Staff  

  • 1993.09

    Nagasaki University, Department of Hematology, Senior Resident  

display all >>

Research Interests 【 display / non-display

  • clinical study

Research Areas 【 display / non-display

  • Life Science / Hematology and medical oncology

Published Papers 【 display / non-display

  • A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia/lymphoma: combination of RNA in situ hybridization and quantitative PCR for HTLV-1.

    Takatori M, Sakihama S, Miyara M, Imaizumi N, Miyagi T, Ohshiro K, Nakazato I, Hayashi M, Todoroki J, Morishima S, Masuzaki H, Fukushima T, Karube K

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc ( Modern Pathology )    2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.

    Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M

    Journal of hepatology   73 ( 2 ) 285 - 293   2020.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    BACKGROUND & AIMS: The purpose of this post hoc analysis was to evaluate the efficacy of an ultra-high sensitive HBsAg assay using prospectively stored samples of HBV DNA monitoring study for lymphoma patients with resolved HBV infection following anti-CD20 antibody, rituximab-containing chemotherapy (UMIN000001299). METHODS: HBV reactivation defined as HBV DNA levels of 11 IU/mL or more was confirmed in 22 of 252 patients. Conventional HBsAg assay (ARCHITECT, cut-off value: 0.05 IU/mL) and ultra-high sensitive HBsAg assay employing a semi-automated immune complex transfer chemiluminescence enzyme technique (ICT-CLEIA, cut-off value: 0.0005 IU/mL) were measured at baseline, at confirmed HBV reactivation and monitored after HBV reactivation. RESULTS: Baseline HBsAg was detected using ICT-CLEIA in 4 patients, in all of whom precore mutants with high replication capacity were reactivated. Of the 6 patients with HBV DNA detected below the level of quantification at baseline, 5 showed HBV reactivation and 3 of the 5 had precore mutations. Sensitivity for detection by ARCHITECT and ICT-CLEIA HBsAg assays at HBV reactivation or the next sampling after HBV reactivation was 18.2% (4 of 22) and 77.3% (17 of 22), respectively. Of the discrepant 5 patients undetectable by ICT-CLEIA, 2 patients resolved spontaneously. All 6 patients reactivated with precore mutations including preS deletion could be diagnosed by ICT-CLEIA HBsAg assay at an early stage of HBV reactivation. Multivariate analysis showed that an anti-HBs titer of less than 10 mIU/mL, detected HBV DNA below the level of quantification, and detected ICT-CLEIA HBsAg at baseline were independent risk factors for HBV reactivation (adjusted hazard ratios, 15.4, 31.2 and 8.7, respectively; p<0.05). CONCLUSIONS: A novel ICT-CLEIA HBsAg assay would be an alternative method to diagnose HBV reactivation.

  • Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL.

    Guerrero CLH, Yamashita Y, Miyara M, Imaizumi N, Kato M, Sakihama S, Hayashi M, Miyagi T, Karimata K, Uchihara J, Ohshiro K, Todoroki J, Nakachi S, Morishima S, Karube K, Tanaka Y, Masuzaki H, Fukushima T

    Blood advances ( Blood Advances )  4 ( 6 ) 1062 - 1071   2020.03 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.

    Nagate Y, Ezoe S, Fujita J, Okuzakis D, Motooka D, Ishibashi T, Ichii M, Tanimura A, Kurashige M, Morii E, Fukushima T, Suehiro Y, Yokota T, Shibayama H, Oritani K, Kanakura Y

    Leukemia ( Leukemia )    2020.03 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Conservation of a Neutralization Epitope of Human T-cell Leukemia Virus Type 1 (HTLV-1) among Currently Endemic Clinical Isolates in Okinawa, Japan.

    Mizuguchi M, Takahashi Y, Tanaka R, Fukushima T, Tanaka Y

    Pathogens (Basel, Switzerland) ( Pathogens )  9 ( 2 )   2020.01 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    Approximately one-tenth of the 10 million individuals living with human T-cell leukemia virus type-1 (HTLV-1) worldwide live in Japan. Most of these infected individuals live in the southwest region of Japan, including Okinawa prefecture; however, currently no prophylactic vaccine against HTLV-1 infection is available. For preventing the HTLV-1 spread, we previously generated a humanized monoclonal antibody (hu-LAT-27) that mediates both neutralization and antibody-dependent cellular cytotoxicity (ADCC). The neutralization epitope of LAT-27 is a linear amino acid sequence from residue 191 to 196 (Leu-Pro-His-Ser-Asn-Leu) of the HTLV-1 envelope gp46 protein. Here, we found that the LAT-27 epitope is well conserved among HTLV-1 clinical isolates prevalent in Okinawa. The hu-LAT-27 treatment inhibited syncytium formation by these clinical HTLV-1 isolates. Although an amino acid substitution at residue 192 in the LAT-27 epitope from proline to serine was found in a few HTLV-1 isolates, hu-LAT-27 could still react with a synthetic peptide carrying this amino acid substitution. These findings demonstrate the wide spectrum of hu-LAT-27 reactivity, suggesting that hu-LAT-27 may be a candidate drug for prophylactic passive immunization against HTLV-1 infection.

display all >>

Books 【 display / non-display

  • Adult T-cell Leukemia/Lymphoma

    Fukushima Takuya ( Part: Single Author ,  Prognosis and Prognostic Index )

    Tokyo: Springer Japan  2017

  • Therapeutic angiogenesis by autologous transplantation of bone marrow mononuclear cells for peripheral artery disease. International Congress Series 1299, Radiation Risk Perspective

    Nagai K, Matsumaru K, Fukushima T, Miyazaki Y, Yamaguchi H, Kamihira S, Eishi K, Tomonaga M. ( Part: Multiple Authorship )

    ELSEVIER  2007

Other Papers 【 display / non-display

Preferred joint research theme 【 display / non-display

  • Clinical Research of Adult T-cell leukemia-lymphoma